Navigation Links
Inimex Pharmaceuticals begins First Clinical Study of an Innate Defense Regulator
Date:4/28/2009

    Phase 1 healthy volunteer study of IMX942 will provide human safety and
    pharmacodynamic data

VANCOUVER, April 28 /PRNewswire/ - Inimex Pharmaceuticals is pleased to announce that its novel Innate Defense Regulator (IDR) IMX942 was administered to human subjects for the first time on April 27, 2009. The healthy volunteers were enrolled in a Phase 1 safety study of IMX942 being performed for Inimex in Montreal with the approval of Health Canada.

"With this transition of IMX942 into clinical development, we are looking forward to demonstrating the safety and biological effects of our IDR drugs in humans," explains Dr. John R. North, President and CEO of Inimex Pharmaceuticals, Inc. "We are excited that we will soon be in a position to test IMX942, the first of this truly innovative new class of drugs, in patients at risk of infection; we expect to launch the first Phase 2a study during 2010 in the USA under an Investigational New Drug (IND) application."

Inimex Pharmaceuticals secured US$22 Million in Series B venture financing in May 2008, providing the resources to enable the company to conduct the first clinical trials of an IDR drug in patients and to evaluate IDRs in a broad range of disease models. Morningside Venture Investments Ltd. led the Series B syndicate, joined by Astellas Venture Management LLC, BC Advantage Funds (VCC) Ltd., BDC Capital Inc., British Columbia Discovery Fund (VCC) Inc., Canadian Medical Discoveries Fund, Inc., managed by JovInvestment Management, Inc., Roche Venture Fund, and Working Opportunity Fund (EVCC) Ltd., managed by GrowthWorks Capital Ltd.

About IMX942

IMX942 is the first of a new class of drugs known as Innate Defense Regulators, which modulate innate defenses to improve survival, reduce bacterial infections and suppress inflammation. IMX942 is a small, proprietary, fully synthetic peptide that binds to an intracellular adaptor protein and modifies the signaling network downstream of TLR, TNF, and IL-1 receptors. IMX942 has no direct anti-bacterial activity but can control the outcome of infections caused by a broad spectrum of pathogens; in future clinical studies it will be developed for control of infections in high risk patients in the hospital setting.

About Inimex Pharmaceuticals

Inimex Pharmaceuticals Inc. is a privately held biopharmaceutical company dedicated to the discovery, development, and commercialization of new medicines based on the selective modulation of the innate immune response. Inimex' first in class products show promise for the safe and effective treatment of a broad spectrum of serious medical conditions, including infectious diseases and inflammatory disorders. For more information, please visit www.inimexpharma.com.


'/>"/>
SOURCE Inimex Pharmaceuticals Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
5. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
6. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
7. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
8. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
9. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
10. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
11. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... , Jan. 17, 2017  Protagonist Therapeutics, Inc. ... it has initiated a global Phase 2b induction ... peptide that targets alpha4beta7 integrin. The aim of ... to evaluate the safety/tolerability and efficacy of PTG-100 ... moderate to severe active disease. ...
(Date:1/16/2017)... --  Valentin A. Pavlov, PhD , associate investigator, and ... of The Feinstein Institute for Medical Research ... nervous system regulates the immune system, which will help ... devices to treat disease and injury. The analysis is ... The paper examines various studies which further define the ...
(Date:1/14/2017)... Diego, CA (PRWEB) , ... January 14, 2017 ... ... of Proximo™, a new service providing complete end-to-end genome assemblies to researchers around ... complete genomes eliminates a major obstacle in answering a wide range of scientific ...
(Date:1/13/2017)... Research and Markets has announced the addition of the ... ... a CAGR of 16.83% during the period 2017-2021. The ... biopolymers market for 2017-2021. To calculate the market size, the report considers ... report also includes a a discussion of the key vendors operating in ...
Breaking Biology Technology:
(Date:12/15/2016)... 2016 ... Research and Markets has announced the addition of the ... The report forecasts the global military biometrics market to grow at ... report has been prepared based on an in-depth market analysis with inputs ... prospects over the coming years. The report also includes a discussion of ...
(Date:12/12/2016)... 2016  Researchers at Trinity College, Dublin, are ... combining the material with Silly Putty. The mixture (known ... able to sense pulse, blood pressure, respiration, and ... The research team,s findings were published ... http://science.sciencemag.org/content/354/6317/1257 ...
(Date:12/7/2016)... December 7, 2016 BioCatch , the global ... its patent portfolio, which grew to over 40 granted and pending patents. ... , , ... patent entitled " System, Device, and Method Estimating Force Applied ... device makers to forego costly hardware components needed to estimate the force ...
Breaking Biology News(10 mins):